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Abstract
Purpose
Because cytidine deaminase (CDA) is the key enzyme in gemcitabine metabolism, numer-
ous studies have attempted to investigate impact of CDA status (i.e. genotype or pheno-
type) on clinical outcome. To date, data are still controversial because none of these
studies has fully investigated genotype-phenotype CDA status, pharmacokinetics and clini-
cal outcome relationships in gemcitabine-treated patients. Besides, most patients were
treated with gemcitabine associated with other drugs, thus adding a confounding factor. We
performed a multicenter prospective clinical trial in gemcitabine-treated patients which
aimed at investigating the link between CDA deficiency on the occurrence of severe toxici-
ties and on pharmacokinetics, and studying CDA genotype-phenotype relationships.
Experimental design
One hundred twenty patients with resected pancreatic adenocarcinoma eligible for adjuvant
gemcitabine monotherapy were enrolled in this study promoted and managed by the Fédér-
ation Francophone de Cancérologie Digestive. Toxicities were graded according to National
Cancer Institute’s Common Terminology Criteria for Adverse Events Version 4. They were
considered severe for grade 3, and early when occurring during the first eight weeks of
treatment. CDA status was evaluated using a double approach: genotyping for 79A>C and
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functional testing. Therapeutic drug monitoring of gemcitabine and its metabolite were per-
formed on the first course of gemcitabine.
Results
Five patients out of 120 (i.e., 4.6%) were found to be CDA deficient (i.e., CDA activity <1.3
U/mg), and only one among them experienced early severe hematological toxicity. There
was no statistically significant difference in CDA activity between patients experiencing
hematological severe toxicities (28.44%) and patients who tolerated the treatment
(71.56%). CDA genetic analysis failed in evidencing an impact in terms of toxicities or in
CDA activity. Regarding pharmacokinetics, a wide inter-individual variability has been
observed in patients.
Conclusion
This study, which included only 4.6% of CDA-deficient patients, failed in identifying CDA
status as a predictive marker of toxicities with gemcitabine. A lack of statistical power
because of smoothing effect of CDA variability as compared with real life conditions could
explain this absence of impact.
Trial Registration
ClinicalTrials.gov NCT01416662
Introduction
Gemcitabine is an antimetabolite drug widely prescribed to treat various types of cancer, from
solid tumors to hematological disorders such as pancreatic adenocarcinoma, non-small cell
lung cancer, sarcoma or lymphoma, alone or in combination with others cytotoxics such as
capecitabine, nab-paclitaxel or oxaliplatin [1–5]]. Since identification of cytidine deaminase
(CDA) as the key enzyme involved in the metabolic pathway of gemcitabine in the early 90’s
[6], many studies have been conducted to try to better understand whether changes in CDA
activity could impact on efficacy and toxicity of gemcitabine-based regimen [7] The existing
wide inter-individual variability in CDA activity allows patients to be sorted into 3 categories:
poor metabolizers (PM), defined with a reduced CDA activity (CDA<1.3 U/mg), ultra-deami-
nators (UM), individuals with an increased CDA activity (>6 U/mg) and patients with a nor-
mal CDA phenotype (extensive metabolizers, EM) showing a median activity of 3.2 in adults
and 3.4 U/mg in children [8].
This marked variability among activities is partly linked to genetic and epigenetic polymor-
phisms [9]. CDA is indeed a highly polymorphic gene [10], with synonymous variations in
intron with little consequence on the phenotype to non-synonymous non-sense polymor-
phisms leading to a truncated protein [11]. Some of these variations have been well studied
with respect to clinical outcome upon gemcitabine intake. Among them, the non-synonymous
rs2072671 encodes for a substitution of a lysine into a glutamine because of a replacement of
the adenine by a cytosine in position 79 in the coding sequence. According to Micozzi et al.
[12], this modification in the amino-acid sequence does not impact on the catalytic event.
Many studies have been performed to establish clear correlation between this polymorphism
and CDA phenotype [7]. To date, Giovannetti et al. and Baker et al. correlated the wild type
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genotype (A/A encoding for Lys27Lys enzyme) with a lower mean CDA activity [11, 13, 14]
while our team did not clearly evidence a link between CDA genotype and functionality with
respect to cytidine deamination [8]. Very recently, the impact of 79A>C polymorphism on the
response and hematological toxicities in gemcitabine-treated patients has been studied in a
meta-analysis, encapsulating 6 studies performed in 2013 [15]. This meta-analysis suggested
that the A/A genotype seems to be a protective factor with respect to incidence of severe ane-
mia, whereas the C/C genotype did not show a significant impact on the response rate in non-
small cell lung cancer (NSCLC) patients treated with gemcitabine.
A decrease in CDA activity leads to a decrease of gemcitabine clearance. We already evi-
denced an overexposure to gemcitabine due to CDA deficiency in mice treated with gemcita-
bine [8]. Many published studies in human have confirmed these results, reporting a decrease
in gemcitabine clearance correlated with either a given CDA genotype [15, 16] or reduced
deamination function [7, 8, 17]. Conversely, we have shown that UM pancreatic cancer
patients (i.e., CDA activity> 6 U/mg) were 5-times more likely to have progressive disease
upon gemcitabine intake, as compared with patients with normal CDA status [18]. Despite the
lack of pharmacokinetic support in this study, this may be explained by an over-elimination of
gemcitabine by the CDA hyperactivity, thus resulting in lack of efficacy.
To date, none of these studies fully investigated genotype-phenotype-pharmacokinetics and
clinical outcome relationships with gemcitabine. Such a study would highlight how genetic
events could influence the functional activity of CDA, thus confirming that CDA status is a
predictive factor of a decrease in gemcitabine clearance, with consequently a higher incidence
of severe toxicity. Here, we performed a prospective clinical trial in gemcitabine-treated
patients with resected pancreatic cancer which aimed at investigating the impact of CDA defi-
ciency on the occurrence of toxicities and on pharmacokinetics, but also to better understand
CDA genotype-phenotype relationships. This study was promoted and managed by the Fédér-
ation Francophone de Cancérologie Digestive (FFCD).
Patients & Methods
Objectives
The main objective of this trial was to evaluate the ability of CDA to predict the occurrence of
early severe hematological toxicity upon gemcitabine. The secondary objectives were to evalu-
ate the capability of CDA to predict the occurrence of early severe non hematological toxicities,
and the hematological toxicities induced by gemcitabine overall the treatment, to evaluate the
impact of CDA activity on pharmacokinetics of gemcitabine and its metabolite, and to study
CDA genotype-phenotype relationships. An exploratory analysis was planned to study if CDA
could be a prognostic factor and a marker for gemcitabine efficacy.
Patients and treatment
Adult patients with resected pancreatic adenocarcinoma (R0: resection for cure or R1: micro-
scopic residual tumor) were included from 31 French clinical centers in this study. Main non-
inclusion criteria were metastatic or locally advanced disease, presence of infectious syndrome,
and previous chemotherapy (within the ten years before inclusion). All patients were eligible
for adjuvant gemcitabine-monotherapy as follows: 30-minutes IV-infusion of 1000 mg/m2
every week for 3 consecutive weeks followed by one week off for 6 courses. Demographic (e.g
age, sex weight, body surface area), clinical (e.g. tumor size, localization, and tumor classifica-
tion using TNM, disease grade, World Health Organization (WHO) status, resection margin)
and biological data (e.g. data about liver, renal and cardiac functions, whole blood count) were
collected prior and during treatment. Toxicities were graded according to the National Cancer
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Institute’s Common Terminology Criteria for Adverse Events Version 4. Toxicities were con-
sidered as severe for grade 3, and early when they occurred during the first eight weeks of
treatment. Written informed consent was provided prior enrolment in accordance with the
Declaration of Helsinki and this study was approved by local ethical committee (Comité de
Protection des Personnes Sud Méditerranée 1) in January 2011. The authors confirmed that all
ongoing and related trials for this drug are registered: trial was registered at the ANSM as
2010-022987-11 and on the clinicaltrial.gov website in June 2011. The patients were recruited
between July 2011 and June 2013 with a 2-years follow-up (Fig 1, S1 Checklist and S1
Protocol).
Determination of CDA status
CDA status was evaluated using a double approach: a phenotypic assay and a genetic analysis.
Blood samples (one dry tube and one EDTA tube for evaluation of CDA activity and genotyp-
ing test, respectively) were collected from patients prior to treatment. Seric fraction was isolated
after centrifugation of the dry tube, whereas lymphocyte DNA was extracted from the EDTA
tube using EZ1 DNA Blood Kit (Qiagen). DNA and seric fraction was then conserved at -20
and -80°C respectively until analysis. CDA activity was evaluated using a previously developed
method, already used in a routine clinical practice in our hospital [8]. Briefly, as CDA is physio-
logically responsible for the deamination of cytidine by releasing ammonium, patients serum
were incubated overnight ex vivo with cytidine and the quantity of released ammonium was
measured by visible spectrophotometry. Seric proteins amount was also assayed using Pierce
method as CDA activity is finally expressed with respect to the seric proteins amount. Patients
were considered as PM when their CDA activity was1.3 U/mg, a threshold previously deter-
mined from our retrospective study [8]. As CDA rs2072671 SNP (i.e. 79A>C) is the most com-
mon non-synonymous exonic variant found in the Caucasian population [12], we screened for
this genetic polymorphism in the cohort, using High Resolution Melting (HRM) analysis on
LightCycler480. After amplification of each patient DNA in duplicate, the melting curve (from
70° to 95°C) was compared to standards in order to establish the genotype.
Fig 1. Consort flowchart of the primary objective in the FFCD-1004 clinical trial.
doi:10.1371/journal.pone.0135907.g001
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Gemcitabine and dFdU therapeutic drug monitoring (TDM)
A pharmacokinetic study was performed. It consisted in sampling patients during the first
round of gemcitabine administration to evaluate circulating plasma levels of both gemcitabine
and its inactive metabolite dFdU. Blood samples were collected before starting the infusion,
at the end and 30 and 90 minutes after the end of infusion in EDTA tube containing tetrahy-
drouridine (THU) to prevent in silico deamination by CDA. Plasma fraction was immediately
isolated after centrifugation and aliquots were stocked at -80°C until analysis. Gemcitabine and
dFdU were simultaneously measured using LC-MSMS assay, adapted from by Zhou et al. [19],
and validated according to European Medicines Agency (EMA) and Food and Drug Adminis-
tration (FDA) guidelines. Briefly, 50 μl of drug-free plasma and 500 μl of precipitating solution
containing acetonitrile and internal standard (abacavir ABC) are added to a 50-μl test sample.
After vortex-mixing for 90 sec, samples were centrifuged during 10 minutes at 14 000 rpm at
room temperature. The supernatant was then dry evaporated under a gentle stream of nitrogen
at 45°C and the residue was dissolved in 600 μl of reconstitution solvent (5 mM ammonium
acetate + 0.1% formic acid) by vortex-mixing for 15 sec. Then, samples were transferred into
96-well plate before analysis.
Chromatographic separations of gemcitabine, dFdU and ABC were performed on an UPLC
system (Waters UPLC-TQD), using an Acquity UPLC HSS T3 column (1.8 μm x 2.1 x 100mm,
Waters) maintained at 40°C. The mobile phase was composed of an acetate buffer (5 mM
ammonium acetate, 0.1%, formic acid) as aqueous phase and an organic phase composed of
acetonitrile. A 5 μl-volume sample was injected and eluted with a gradient of aqueous and
organic phases at a constant flow rate of 0.250 ml/min for a total run time of 6 minutes. A
Waters tandem quadrupole detection system with an electrospray ionization (ESI) source oper-
ating in positive mode for gemcitabine and ABC and negative mode for dFdU was used to
obtain mass and product ion spectra (MS and MS-MS). MassLynx software version 4.1 was
used for data acquisition and processing. Mass transitions ofm/z 264.05 -> 112.05, 287.10 ->
191.10 were optimized for gemcitabine and ABC, respectively. For dFdU, two transitions have
been used: 263.05 -> 111.05 for quantification and 263.05 -> 219.95 for qualification.
The resulting pharmacokinetics data were analyzed using pharmacokinetics software Kine-
ticPro (WGroup, France). Bayesian estimation was used to estimate individual pharmacokinet-
ics parameters and to simulate plasma exposure of patients, based on previously published
pharmacokinetic parameters [20].
Statistical analysis
The main objective of the trial was to evaluate the capability of CDA to predict the occurrence
of early severe hematological toxicity upon gemcitabine. In order to bring out a positive likeli-
hood ratio of CDA more than 3.5 (H1), objective reached when sensitivity is more than 70%
and specificity is more than 80% with an α risk of 5% and a power of 80%, 107 patients had
to be included. With an estimated 10% of lost-to-follow-up patients or patients not treated,
120 patients were finally included. The probability of severe hematological toxicity without
CDA knowledge was estimated at 12.5%, based on retrospective published data [8]. Primary
criterion, safety secondary endpoints (i.e., overall toxicities and non-hematological ones)
and exploratory analyses were done on the set of patients receiving at least one dose of gemcita-
bine and with a CDA fully evaluable status. The primary criterion was measured with positive
and negative likelihood ratios, sensitivity and specificity, and the positive and negative predic-
tive values (with their 95% confidence intervals). Time to event endpoints (e.g time to grade
3–4 hematological (or non-hematological) toxicity appearance as-well-as overall survival)
were estimated using Kaplan-Meier method. A series of clinical parameters measured at the
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inclusion were evaluated as prognostic factors on the overall survival in a univariate and a mul-
tivariate analyses. We also tested the influence of 79A>C genotype on incidence of severe tox-
icities using Chi2-test. In this aim, we gathered the heterozygous and homozygous mutated
patients as “mutated” patients’ status.
Results
Patients and clinical outcome
One hundred and twenty patients have been included in this prospective study, from 31 differ-
ent French centers, with a mean age of 65.8 years (sd 10.05) and a sex ratio of 1.61 (Table 1).
One hundred and nineteen patients (99.9%) have received at least one dose of gemcitabine.
The median survival was 29.08 months [95% CI, 25.1 to NA], with 6-months and
12-months survival rates of 95.8 and 79.82%, respectively. In terms of toxicity, 25 (23%)
patients declared early severe hematological toxicities, 20 (18%) displayed other early severe
toxicities. Maximal gemcitabine caused-toxicities during treatment are summarized in Table 2.
CDA status
One hundred and nine and ninety-two patients were analyzable for CDA phenotyping and
genotyping tests, respectively. Five patients out of 109 (i.e. 4.6%) were found to be PM and one
patient (i.e. 0.9%) displayed CDA activity greater than 6 U/mg (UM). Among the CDA-defi-
cient patients, only one experienced early severe hematological toxicities. Median CDA activity
was not significantly different between patients who had early severe toxicities and patients
with no such toxicities (2.35 vs 2.25 respectively p>0.05, Table 3). In the same manner, with
respect to severe hematological and non-hematological toxicities all over the treatment, CDA
activity was also similar when comparing patients with toxicities and patients with no toxici-
ties. Age and disease stage at the diagnostic were both correlated with overall survival in
Table 1. Patients’ characteristics.
Clinical characteristics Clinical characteristics subgroups Number of patients (%) N = 120
Sex male 74 (61.7%)
female 46 (38.3%)
Age median 66.72
minimum 30.6
maximum 84.9
WHO performance status 0 46 (38.3%)
1 68 (56.7%)
2 6 (5.0%)
Tumor localization head 96 (80.0%)
body 8 (6.7%)
tail 11 (9.2%)
head and body 1 (0.8%)
head and tail 1 (0.8%)
body and tail 3 (2.5%)
Disease grade (TNM classiﬁcation) T1/T2 24 (20.0%)
T3/T4 96 (80.0%)
N+ 84 (70.0%)
Resection margin R0 106 (88.3%)
R1 14 (11.7%)
doi:10.1371/journal.pone.0135907.t001
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univariate and multivariate analysis (Table 4), whereas no influence of CDA activity could be
evidenced neither on the overall survival (p = 0.28 in univariate analysis).
Studying CDA genotype showed that 59.8% of patients displayed the 79A>C polymor-
phism. No correlation was evidenced between this CDA genotype and occurrence of toxicities,
whether hematological or not, and CDA activity was similar in mutated patients group and the
non-mutated patients group (p = 0.61).
Pharmacokinetic study
A total of 39 out of the 120 patients (33%) initially involved in the clinical trial were enrolled in
the additional pharmacokinetic study (Fig 2). Administration protocol was not strictly
respected for 9 patients (infusion time superior to 45 minutes) and kinetics were not complete
Table 2. Maximal gemcitabine-caused toxicities over treatment.
Types of toxicity Subtypes of toxicity No. of patients (%)
Toxicity grades Grades 1–2 Grades 3–4
Hematological Anemia 110 (92.4%) 5 (4.2%)
Leucopenia 81 (68.1%) 9 (7.6%)
Neutropenia 64 (53.8%) 30 (25.2%)
Thrombopenia 62 (52.1%) 1 (0.8%)
Non hematological Nausea 65 (54.6%) 1 (0.8%)
Vomiting 33 (27.7%) 0 (0%)
Diarrhea 66 (55.5%) 1 (0.8%)
Asthenia 90 (75.6%) 3 (2.5%)
doi:10.1371/journal.pone.0135907.t002
Table 3. Toxicities during treatment according to CDA activity (n = 109).
No. of patients with severe hematological toxicities in the ﬁrst eight
weeks of treatment (%)
no yes p-value
n 84 25
CDA median activity 2.25 2.35 p = 0.87
Q1-Q3 1.80–2.80 1.89–3.32
CDA  1.3 U/mg vs. > 1.3 U/mg 4 (4.76%) vs. 80 (95.24%) 1 (4%) vs. 24 (96%) p = 0.99
Total 84 (100%) 25 (100%) 109 (100%)
No. of patients with severe hematological toxicities all over the
treatment (%)
no yes p-value
CDA median activity 2.25 2.35 p = 0.67
Q1-Q3 1.78–2.82 1.89–3.11
CDA  1.3 U/mg vs. > 1.3 U/mg 4 (5.13%) vs. 74 (94.87%) 1 (3.23%) vs. 30 (96.77%) p = 0.99
Total 78 (100%) 31 (100) 109 (100%)
No. of patients with severe non hematological toxicities all over the
treatment (%)
no yes p-value
CDA median activity 2.215 2.3 p = 0.15
Q1-Q3 1.73–3.02 1.99–2.82
CDA  1.3 U/mg vs. > 1.3 U/mg 5 (6.41%) vs. 73 (93.6%) 0 (0%) vs. 31 (100%) p = 0.32
Total 78 (100%) 31 (100%) 109 (100%)
doi:10.1371/journal.pone.0135907.t003
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Table 4. Median overall survival according to different criteria.
Clinical criteria Median overall survival (months) 95% CI
Age <65 y.o vs. 65 y.o 34.4 vs. 26.5 p = 0.0253 [25.7-NA] vs. [20.9–31.3]
Disease stage T1-T2 vs.T3-T4 31.3 vs. 29 p = 0.0408 [25.1—NA] vs. [20.9—NA]
doi:10.1371/journal.pone.0135907.t004
Fig 2. Pharmacokinetics profiles of gemcitabine (A) and its metabolite (B) overtime during the first round of gemcitabine administration in
pancreatic adenocarcinoma cancer patients. Patients have been sampled before infusion, at the end, and 90 and 120 minutes after ending the infusion. A
wide inter-individual variability is observed, either for gemcitabine or for dFdU.
doi:10.1371/journal.pone.0135907.g002
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for 2 patients. Among patients with a carefully-driven administration protocol, gemcitabine
plasma concentrations ranged from 19.8 to 2.77 μg/ml at end of infusion and AUC from
1.23x105 to 4.80x108 ng/mlmin, thus evidencing a wide inter-individual variability in gemcita-
bine exposure in patients.
Discussion
Developing and implementing new tests in a routine clinical practice allowing to stratify
patients according to their characteristics has become a rising trend. To date, many pharmaco-
genomic tests are available to ensure a better response with respect to the treatment in patients.
Additionally, some pharmacogenetic assays are recommended to be performed prior to the
start of treatment, such as TMPT for azathioprine or 6-mercaptopurine [21]. Regarding to
CDA, since evidence has been made that it is the key enzyme involved in gemcitabine deactiva-
tion, many studies focused on CDA status and toxicities or pharmacokinetics relationships. All
studies are consistent with the fact that an impairment in CDA functionality leads to gemcita-
bine overexposure caused by a decrease in gemcitabine liver clearance. However, with respect
to the 79A>C SNP, available data are not consistent, when not conflictual [14, 22–24]. The dis-
crepancies in CDA pharmacogenetic studies partly explain why there is still no recommenda-
tion for testing CDA at bedside before initiating gemcitabine-treatment. Thus, ensuring a
better tolerance of gemcitabine and a better management of toxic risk in patients treated with
gemcitabine depends only on the goodwill on the medical team, and on the availability of a sur-
rogate CDA test in the institute. Here, we proposed a prospective study to confirm whether
CDA status could be a predictive factor of toxicities in patients under gemcitabine-based
Fig 3. Boxplots of CDA activity in prospective compared to retrospective study.CDAretro stands for CDA activity in gemcitabine-treated patients for
various types of cancers in the retrospective study. The boxplot in the middle represents CDA activity in the subgroup of gemcitabine-monotherapy patients
in the retrospective study. CDA activities of patients from the prospective study are represented in the boxplot on the right. Isolating gemcitabine-
monotherapy treated patients leads to a smoothing effect in CDA activity variability.
doi:10.1371/journal.pone.0135907.g003
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treatment. The originality of this study was to address the issue of genotype, phenotype, phar-
macokinetics and clinical outcome. The study confirmed the wide inter-individual variability
in pharmacokinetics, already described elsewhere [8, 25]. Regarding to CDA, unfortunately, no
association between CDA genotype nor CDA phenotype and toxicity was evidenced here. This
absence of significant association between CDA and toxicity could be explained by the surpris-
ingly weak proportion of CDA-deficient patients in this study. Indeed, the design of this study
was inspired from a previous one [8], involving unselected patients treated with gemcitabine
alone or in combination for various types of cancers. In this previous retrospective study
involving routine patients of our institute, 10% of individuals were PM according to CDA and
we showed that patients with decreased CDA activity were significantly more at risk to experi-
ence severe toxicities. However, this was not confirmed in the subgroup of pancreatic cancer
patients treated with gemcitabine only, suggesting a lack of statistical power. In this new study,
variability of CDA was found to be considerably reduced when compared to the first trial, but
comparable to the retrospective pancreatic patients subgroup (Fig 3). Only 4.59% of patients
displayed CDA deficiency, thus preventing to perform any statistical test. This low incidence of
CDA deficiency may be explained by a smoothing effect due to performing a clinical trial with
overselected patients. Similarly, only 0.9% of patients displayed UM phenotype, while 14%
were found in the previous study [18]. Here, drastic inclusion criteria used to meet the require-
ments of a prospective trial apparently had a negative impact on CDA natural variability.
To summarize, this prospective study failed in identifying CDA as a predictive marker of
toxicities under gemcitabine treatment. A lack of statistical power because of smoothing effect
of CDA variability as compared with real life conditions could explain this.
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